Skip to main content

Table 2 Best overall response

From: Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

Parameter

N (%)

P

Overall (n = 110)

Before amendment (n = 67)

After amendment (n = 43)

Morphologic response

 CR

69 (63)

40 (60)

29 (67)

0.41

 CRp

19 (17)

10 (15)

9 (21)

0.42

 CRi

3 (3)

1 (1)

2 (5)

0.32

 ORR

91 (83)

51 (76)

40 (93)

0.02

MRD negativity

 At response

47/87 (54)

28/49 (57)

19/38 (50)

0.51

 Overall

75/89 (84)

41/50 (82)

34/39 (87)

0.51

No response

12 (11)

9 (13)

3 (7)

0.29

Early death

7 (6)

7 (10)

0

0.03

MRD negativity

 Salvage 1

    

  At response

41/70 (59)

23/33 (70)

18/37 (49)

0.08

  Overall

65/73 (89)

31/34 (91)

34/39 (87)

0.59

 ≥ Salvage 2

    

  At response

6/17 (35)

5/16 (31)

1/1 (100)

0.17

  Overall

12/18 (67)

10/16 (63)

2/2 (100)

0.29

  1. CR Complete response; CRi CR with incomplete hematologic recovery; CRp CR without platelets recovery; MRD Measurable residual disease; ORR Overall response rate